
|Videos|November 16, 2022
Captisol- Why it’s the UNRIVALED Modified Cyclodextrin
Author(s)Ligand
Key Learning Objectives
- Captisol is in over a dozen FDA approved products with multiple product approvals coming in the next year. These approvals include oral and ophthalmic routes of administration. Proven safe!
- A team of experts with 20+ years of experience who are ready to answer any questions are what sets Captisol apart from other modified cyclodextrins.
- Ligand formulation services are now available to assist with consideration of CAPTISOL for solving product development issues and achieving Target Product Profile goals
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Trending on Pharmaceutical Technology
1
Industry Outlook 2026: Navigating AI, Sustainability, and Operational Resilience
2
Integrating AI and Machine Learning in Drug Discovery and Development
3
Single-Use Systems Enable Commercial-Scale CGT Manufacturing
4
Pharmaceutical Supply Chain Resilience in a Shifting Market
5




